Tocolysis and preterm labour

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 6, 2004, Pages 459-463

  King, James Forrester ^a,b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Atosiban; Betamimetics; Calcium channel blockers; Magnesium sulphate; Tocolysis

Indexed keywords

ATOSIBAN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MAGNESIUM SULFATE; NICARDIPINE; NIFEDIPINE; OXYTOCIN ANTAGONIST; PLACEBO; PROSTAGLANDIN INHIBITOR; ROFECOXIB; UTERUS SPASMOLYTIC AGENT; ARGIPRESTOCIN; DRUG DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR;

BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FETUS LUNG MATURITY; HUMAN; LUNG EDEMA; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN INTENSIVE CARE; PERINATAL MORBIDITY; PERINATAL MORTALITY; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; TOCOLYSIS; UTERUS CONTRACTILITY; FEMALE; PREGNANCY;

CALCIUM CHANNEL BLOCKERS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MAGNESIUM SULFATE; OBSTETRIC LABOR, PREMATURE; PREGNANCY; TOCOLYSIS; TOCOLYTIC AGENTS; VASOTOCIN;

EID: 16644378261     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200412000-00004     Document Type: Review

References (25)

1. Alanen A. Does screening reduce preterm births? [commentary]. BMJ 2004; 329:374.
2. Kiss H, Petricevic L, Husslein P. Prospective randomized controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ 2004; 329:371-374.
3. Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003; 101:517-522.
4. Iams JD. The epidemiology of preterm birth. Clin Perinatol 2003; 30:651-664. This paper provides a comprehensive overview of the aetiological components of preterm birth, and the reasons why the rates of preterm birth are increasing.
5. The Consultative Council on Obstetric and Paediatric Mortality and Morbidity. Annual report for the year 2002. Department of Human Services, Melbourne; 2004.
6. Lamont RF. Looking to the future. BJOG 2003; 110 (Suppl 20):131-135.
7. Klaus F. The role of infection in preterm labour. BJOG 2003; 110 (Suppl 20):52-54.
8. Cook C-M, Peek M. Survey of the management of preterm labour in Australia and New Zealand in 2002. Aust N Z J Obstet Gynaecol 2004; 44:35-38.
9. Klam SL, Leduc L. Management options for preterm birth in Canada. J Obstet Gynaecol Can 2004; 26:339-345.
10. Ingemarrson I, Lamont RF. An update on the controversies of tocolytic therapy for the prevention of preterm birth. Acta Obstet Gynecol Scand 2003; 82:1-9.
11. ACOG Practice Bulletin no. 43: management of preterm labor vol 101. Obstet Gynecol 2003; 5:1039-1047.
12. Higby K, Xenakis EMJ, Pauerstein CJ. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am J Obstet Gynecol 1993; 168:1247-1259.
13. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour [Cochrane review]. The Cochrane Library 2004; Issue 3. Chichester, UK: John Wiley & Sons, Ltd. This systematic review provides convincing evidence that magnesium sulphate should be abandoned as a tocolytic, as it is ineffective and associated with increased adverse outcomes.
14. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290:2669-2676.
15. Mittendorf R, D'Ambrosia J, Pryde PG, et al. Association between the use of antenatal magnesium sulphate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002; 186:1111-1118.
16. King JF, Flenady VJ, Papatsonis DNM, et al. Calcium channel blockers for inhibiting preterm labour [Cochrane review]. The Cochrane Library 2004; Issue 3. Chichester, UK: John Wiley & Sons, Ltd. This systematic review provides convincing evidence that calcium channel blockers such as nifedipine are more effective and safer for the newborn infant than betamimetic agents.
17. Vaast P, Dubreucq-Fossaert S, Houfflin-Debarge V, et al. Acute pulmonary oedema during nicardipine therapy for premature labour: report of five cases. E J O &G and ReproBiol 2004; 113:98-99.
18. King JF, Flenady VJ, Papatsonis DNM, et al. Calcium channel blockers for inhibiting preterm labour: a systematic review of the evidence and a protocol for administration of nifedipine. ANZJOG 2003; 43:192-198.
19. Moise KJ. The effect of advancing gestational age on the frequency of ductal constriction secondary to maternal indomethacin use. Am J Obstet Gynecol 1993; 168:1350-1354.
20. McWhorter J, Carlan SJ, O'Leary TD, et al. Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstet Gynecol 2004; 103:923-930.
21. Valenzuela GJ, Craig J, Bernhardt MD, et al. Placental passage of the oxytocin antagonist atosiban. Am J Obstet Gynecol 1995; 172:1304-1306.
22. Lamont RF. The development and introduction of anti-oxytocic tocolytics. BJOG 2003; 110 (Suppl 200):108-112. One of a very useful series of articles in a special supplement of BJOG, summarizing the development and initial data on this newly developed tocolytic agent.
23. Tsatsaris V, Carbonne B, Cabrol D. Atosiban for preterm labour. Drugs 2004; 64:375-382.
24. Romero R, Sibai BM, Sanchez-Ramos I, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000; 182:1173-1183.
25. Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour [Protocol for a Cochrane review]. The Cochrane Library 2004; Issue 3. Chichester, UK: John Wiley & Sons, Ltd.